{"entity":{"id":"nct07602777","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)","aka":[],"tldr":"A phase 1/2 trial of Ris-Rez in sarcomas, run by GlaxoSmithKline, now recruiting.","summary":"A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202) is a phase 1/2 interventional study registered as NCT07602777 by GlaxoSmithKline, with 113 participants planned, started 2026-06-22 and due to reach its primary completion in 2027-11-18. Interventions recorded: Ris-Rez and G-CSF.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07602777","url":"https://clinicaltrials.gov/study/NCT07602777"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["sarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["gsk"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07602777","phase":"1/2","setting":"Phase 1b/2 Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Previously Treated Unresectable Advanced or Metastatic Sarcomas","sponsor":"GlaxoSmithKline","enrolled":113,"outcomes":[]},"route":"/trials/nct07602777/","neighbours":{"cancer":[{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"}],"company":[{"id":"gsk","kind":"company","name":"GSK","route":"/companies/gsk/"}]}}